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mammography at age 40. OBJECTIVE: To develop a prelimi-
nary model to evaluate the cost-effectiveness of these guidelines,
using similar assumptions and clinical trial evidence sources for
the breast cancer mortality beneﬁt as the ACS. METHODS:
Interventions: Annual mammography until age 70 vs. no annual
mammography. Design: Age-speciﬁc discounted lifetime costs
and discounted quality-adjusted life expectancy were estimated
for each intervention, and the incremental cost-effectiveness ratio
(ICER) calculated. Life-expectancy estimates were generated by
Markov model simulation starting from age 40. Direct costs
included the management of early-stage and invasive breast
cancer, and the costs of mammography and the workup of a pos-
itive result. Indirect costs accounted for the time spent getting
mammograms. BC management costs with and without mam-
mography were assumed to be the same. Time Horizon: Life-
time. Perspective: Societal. Target Population: The model was
estimated in white females aged 40 and over. Data Sources: RCT
Meta-analysis evidence sources used by the ACS, SEER data for
BC mortality and life expectancy, NCHS life-tables data, studies
of mammography performance, and quality of life/health utility
studies. Sensitivity analysis was done to the discount rate, costs,
sensitivity of mammography and costs of mammography.
RESULTS: Base-Case Analysis: The ICER for annual mammog-
raphy until age 70 was extremely high with a minimum value of
$347,442/QALY at age 60. Annual mammography until age 80
was slightly more cost-effective, ranging from $424,058/QALY,
$323,893/QALY and $271,773/QALY at ages 40, 55, and 70
respectively. CONCLUSIONS: Annual mammography starting
from age 40 may turn out to be a very expensive policy. However,
the economic model has some limitations: the mammography
intervention may be associated with different BC management
costs; and the data sources for BC mortality reduction with
mammography have been widely disputed.
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OBJECTIVE: Prostate cancer can have signiﬁcant physical, psy-
chological, and social impact on patients, particularly early in
the treatment course. While psychological intervention during
oncologic care has been shown to improve all aspects of well-
being, few studies have focused on men diagnosed with prostate
cancer or have targeted the period between diagnosis and treat-
ment. We evaluated the efﬁcacy of an innovative, brief psy-
chosocial counseling program delivered to men before and after
prostate cancer treatment. METHODS: One hundred thirty-two
men diagnosed with prostate cancer were randomly assigned to
either intervention (n = 69) or control (n = 63) groups. Partici-
pants completed the Proﬁle of Mood States (POMS), Index of
Coping Responses (ICR), and scales measuring general and
disease-speciﬁc HRQOL, at baseline (before treatment com-
menced) and at months 3 and 12. Both groups received standard
medical care; and intervention participants received 2 sessions of
counseling before treatment and one session 4 to 6 weeks after
treatment completion. RESULTS: Intervention effects were eval-
uated using a mixed model analysis, adjusting for cancer treat-
ment (radiation or surgery) and time. There were no signiﬁcant
differences between groups at baseline on the demographic or
psychosocial measures. In the mixed model, intervention partic-
ipants reported signiﬁcant improvements over time on three out-
comes: Vigor (POMS; p < 0.05) and Information Seeking and
Affective Regulation (ICR; p < 0.01 and p < 0.05, respectively).
CONCLUSIONS: While the brief intervention did not appear to
inﬂuence HRQOL, or prostate-speciﬁc symptoms, it improved
energy level and coping responses, particularly those relevant to
managing information and emotions. These coping strategies
may be especially important given the decision-making and treat-
ment initiation tasks of early prostate cancer care. Source of
ﬁnancial support: California Cancer Research Program Grant
#97–12013.
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OBJECTIVE: To assess the validity and reliability of EORTC
QLQ-C30 in patients with cancer in Singapore. METHODS: A
total of 62 patients at Cancer Center of National University
Hospital were asked to complete independently QLQ-C30 and
a generic questionnaire (SF-36). The sociodemographic data
were obtained simultaneously. RESULTS: The QLQ-C30
demonstrated good internal reliability for most scales with 
Cronbach’s alpha more than 0.7 except cognitive functioning,
physical functioning, and nausea and vomiting scale. The major-
ity of item-scale Pearson’s coefﬁcients (corrected for overlap)
were more than 0.4 and higher as opposed to that between the
item and competing scales in the same instrument. All function-
ing scales in QLQ-C30 had strong correlations with the scales
measuring the similar aspect of QoL in SF-36. The correlation
coefﬁcients among all scales were signiﬁcant but modest (ranging
from an absolute value of 0.23 to 0.65). CONCLUSION: In our
study, QLQ-C30 could be considered reliable and valid using to
evaluate health related quality of life (HRQoL) in cancer patients
in Singapore.
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OBJECTIVE: The majority of head and neck cancer (HNC)
patients undergoing radiation experience xerostomia (dry
mouth) which can range from mild to severe, even after com-
pletion of treatment. Its impact on quality of life (QoL) can be
signiﬁcant. The objective of this study was to evaluate the psy-
chometric properties of a new questionnaire developed to assess
the impact of xerostomia on QoL. METHODS: Data were
obtained from radiation patients (RP) participating in the Eval-
uating Cytoprotection Health Outcomes (ECHO) Registry.
ECHO, a prospective, longitudinal study of patients receiving
amifostine prior to radiation and/or chemotherapy, collects clin-
ical and outcomes information. All RP complete a questionnaire,
including the Functional Assessment of Cancer Therapy-General
(FACT-G) and a new questionnaire assessing xerostomia symp-
toms (XSQ) at baseline, 6-weeks (completion of radiation), and
at 6 weeks, 3 months, and 6 months post treatment. RESULTS:
A total of 104 with HNC, 43 with non-small cell lung cancer
(NSCLC), and 38 with other cancer completed the questionnaire.
